Journal
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
Volume 174, Issue -, Pages 1-8Publisher
ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
DOI: 10.1016/j.ejmech.2019.04.033
Keywords
1,2,4-Triazole; Quinoline; Quinolone; Hybrid compounds; Bacteria; Structure-activity relationship
Categories
Funding
- Science & Technology Innovation Talents of Henan University of Chinese Medicine [2014XCXRC01]
- Henan University of Chinese Medicine, provincial scientific research business [2014KYYWF-ZZCX3-05]
Ask authors/readers for more resources
Bacterial infections, caused predominately by Gram-positive and Gram-negative organisms, are proliferation of harmful strains of bacteria on or inside the body. Hospital-acquired and community-acquired bacterial infections have already put a heavy burden on the global health system. Antibiotics can disrupt the processes necessary for bacterial cell growth and proliferation, are effective weapons to fight against bacterial infections. However, the overuse and misuse of antibiotics have led to a rise in antibiotic resistance, creating an urgent need to develop novel antibiotics. 1,2,4-Triazole-quinoline/quinolone hybrids possess a broad spectrum of chemotherapeutic properties, also demonstrated promising antibacterial activities against both drug-sensitive and drug-resistant bacteria. This review covers the recent advances of 1,2,4-triazole-quinoline/quinolone hybrids as potential anti-bacterial agents. The structure-activity relationship (SAR) is also discussed for further rational development of 1,2,4-triazole hybrids higher potency against both drug-sensitive and drug-resistant pathogens. (C) 2019 Elsevier Masson SAS. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available